vs

Side-by-side financial comparison of NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP (NEN) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP is the larger business by last-quarter revenue ($23.6M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP runs the higher net margin — -677.3% vs -1398.3%, a 721.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 15.7%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 8.9%).

New England Realty Associates Limited Partnership is a real estate investment entity that owns, operates and manages residential and commercial properties primarily across the U.S. New England region. Its core assets include multifamily apartments, mixed-use properties and small commercial spaces, serving tenants across Massachusetts, New Hampshire and adjacent states, delivering steady returns to unitholders via rental income and property value growth.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

NEN vs RNA — Head-to-Head

Bigger by revenue
NEN
NEN
1.9× larger
NEN
$23.6M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+418.3% gap
RNA
434.0%
15.7%
NEN
Higher net margin
NEN
NEN
721.0% more per $
NEN
-677.3%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
8.9%
NEN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NEN
NEN
RNA
RNA
Revenue
$23.6M
$12.5M
Net Profit
$-1.4M
$-174.4M
Gross Margin
Operating Margin
14.0%
-1513.5%
Net Margin
-677.3%
-1398.3%
Revenue YoY
15.7%
434.0%
Net Profit YoY
-133.0%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEN
NEN
RNA
RNA
Q4 25
$23.6M
Q3 25
$23.7M
$12.5M
Q2 25
$21.2M
$3.8M
Q1 25
$20.7M
$1.6M
Q4 24
$20.4M
$3.0M
Q3 24
$20.2M
$2.3M
Q2 24
$20.1M
$2.0M
Q1 24
$19.9M
$3.5M
Net Profit
NEN
NEN
RNA
RNA
Q4 25
$-1.4M
Q3 25
$-521.8K
$-174.4M
Q2 25
$4.1M
$-157.3M
Q1 25
$3.8M
$-115.8M
Q4 24
$4.2M
$-102.3M
Q3 24
$3.9M
$-80.4M
Q2 24
$4.1M
$-70.8M
Q1 24
$3.5M
$-68.9M
Operating Margin
NEN
NEN
RNA
RNA
Q4 25
14.0%
Q3 25
20.0%
-1513.5%
Q2 25
33.3%
-4448.7%
Q1 25
30.1%
-8360.9%
Q4 24
32.4%
-4069.6%
Q3 24
32.0%
-4200.9%
Q2 24
32.6%
-4040.4%
Q1 24
28.9%
-2178.6%
Net Margin
NEN
NEN
RNA
RNA
Q4 25
-677.3%
Q3 25
-2.2%
-1398.3%
Q2 25
19.5%
-4089.3%
Q1 25
18.3%
-7360.0%
Q4 24
20.7%
-3439.5%
Q3 24
19.3%
-3441.7%
Q2 24
20.3%
-3461.8%
Q1 24
17.4%
-1943.4%
EPS (diluted)
NEN
NEN
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEN
NEN
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$26.7M
$350.2M
Total DebtLower is stronger
$531.0M
Stockholders' EquityBook value
$1.9B
Total Assets
$505.3M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEN
NEN
RNA
RNA
Q4 25
$26.7M
Q3 25
$13.4M
$350.2M
Q2 25
$16.7M
$243.9M
Q1 25
$30.9M
$254.2M
Q4 24
$17.6M
$219.9M
Q3 24
$15.1M
$370.2M
Q2 24
$13.5M
$575.8M
Q1 24
$28.8M
$471.4M
Total Debt
NEN
NEN
RNA
RNA
Q4 25
$531.0M
Q3 25
$514.2M
Q2 25
$514.3M
Q1 25
$407.8M
Q4 24
$408.6M
Q3 24
$409.3M
Q2 24
$410.0M
Q1 24
$410.7M
Stockholders' Equity
NEN
NEN
RNA
RNA
Q4 25
Q3 25
$1.9B
Q2 25
$1.2B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$1.2B
Q1 24
$830.9M
Total Assets
NEN
NEN
RNA
RNA
Q4 25
$505.3M
Q3 25
$492.9M
$2.1B
Q2 25
$494.8M
$1.4B
Q1 25
$385.2M
$1.5B
Q4 24
$393.5M
$1.6B
Q3 24
$387.4M
$1.6B
Q2 24
$383.7M
$1.3B
Q1 24
$381.2M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEN
NEN
RNA
RNA
Operating Cash FlowLast quarter
$27.7M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEN
NEN
RNA
RNA
Q4 25
$27.7M
Q3 25
$2.3M
$-156.2M
Q2 25
$12.5M
$-199.7M
Q1 25
$5.5M
$-124.8M
Q4 24
$31.9M
$-99.9M
Q3 24
$8.5M
$-65.6M
Q2 24
$5.4M
$-65.0M
Q1 24
$6.1M
$-70.4M
Free Cash Flow
NEN
NEN
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
NEN
NEN
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
NEN
NEN
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
NEN
NEN
RNA
RNA
Q4 25
Q3 25
Q2 25
3.02×
Q1 25
1.44×
Q4 24
7.57×
Q3 24
2.17×
Q2 24
1.32×
Q1 24
1.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons